44 results about "Mycoplasmata" patented technology

The invention belongs to the technical field of biology, and discloses application of a mycoplasma hyopneumoniae Ebh GA protein in preparation of mycoplasma hyopneumoniae or a multi-combined vaccine containing the mycoplasma hyopneumoniae. The applicant screens out the Ebh GA protein with immunogenicity from the mycoplasma hyopneumoniae for the first time, the Ebh GA protein is shown in SEQ ID NO.7 and can be used as a mycoplasma hyopneumoniae subunit vaccine, and therefore the applicant screens out the protein with immunogenicity of other pathogenic bacteria at the same time and combines the protein with the protein into a quadruple subunit vaccine. The antigens of the obtained quadruple vaccine have a synergistic effect, and compared with a single dose, the quadruple vaccine can enhance the immune effect of the quadruple vaccine.

This application discloses a Mycoplasma pneumoniae P1 protein-binding protein, its preparation method, and its uses. The Mycoplasma pneumoniae P1 protein-binding protein includes an immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3 contained in VHH as shown in any one of SEQ ID NO: 1-8. The bivalent or multivalent nanobodies prepared using this Mycoplasma pneumoniae P1 protein-binding protein can effectively enhance their binding strength to antigens, providing a superior raw material for developing highly sensitive detection and diagnostic applications.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to an anti-mycoplasma pneumoniae antibody, a mycoplasma pneumoniae detection quality control product and a preparation method and application of the mycoplasma pneumoniae antibody and the mycoplasma pneumoniae detection quality control product. The invention provides an anti-mycoplasma pneumoniae antibody which comprises a light chain variable region and a heavy chain variable region, and the light chain variable region and the heavy chain variable region are specifically combined with a C-terminal immunodominance region of mycoplasma pneumoniae P1 protein. Wherein the C-terminal repeat region of the mycoplasma pneumoniae P1 protein is a core immunogenicity region, has high conservative property and strong immunogenicity, can induce a host to generate a specific IgM antibody in the early stage of infection, and is an ideal antibody target. The anti-mycoplasma pneumoniae antibody is obtained by screening through a phage display technology, has high affinity and high specificity, can effectively recognize the C-terminal immunodominance region of the mycoplasma pneumoniae P1 protein, and provides a reliable detection tool for early diagnosis of mycoplasma pneumoniae.

The invention discloses a nucleic acid detection kit for adenovirus, rhinovirus and mycoplasma pneumoniae, and belongs to the field of molecular biological detection. The probe or the detection kit disclosed by the invention comprises one or more of the following primer combinations: a combination I, which comprises primers with sequences of SEQ ID NO.1-3; the combination II comprises primers of which the sequences are SEQ ID NO.4-7; the combination III comprises primers of which the sequences are SEQ ID NO.8-10; and the fourth combination comprises the following steps: replacing the 13th site in the sequence SEQ ID NO.5 in the second combination with G, and / or replacing the 18th site in the sequence SEQ ID NO.7 with T. The lyophilized reagent disclosed by the invention can be used for simultaneously detecting the pulmonary adenovirus, the rhinovirus and the mycoplasma pneumoniae, so that the detection efficiency of respiratory pathogens is improved; the kit is simple in operation, short in time consumption and high in sensitivity, the lowest detection limit of adenovirus, rhinovirus and mycoplasma pneumoniae is 200 copies / mL, the reagent specificity is high, and the detection of viruses with related and similar symptoms is negative.

The invention relates to a novel fusion protein for preventing and treating mycoplasma bovis infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion protein molecular architecture, which comprises fusion proteins coded by two genes of Bmp and FBA, or fusion proteins coded by three genes of EF-Tu, DnaK and EF-G, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The fusion molecule has good immunogenicity, provides an effective immune protection effect, can eliminate bovine mycoplasma colonization in part of individuals, can be used for preventing and treating bovine mycoplasma infection diseases, and has a wide application prospect in animal husbandry.

The invention relates to a pleuromutilin derivative as well as a preparation method and application thereof. The structure of the pleuromutilin derivative is a compound as shown in a formula (I), and a stereoisomer, a tautomer or pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the pleuromutilin derivative. The invention also provides an application of the pleuromutilin derivative in preparation of antibiotics and / or anti-mycoplasma drugs. The invention provides a novel drug which shows good antibacterial activity in vivo and in vitro, so that the problem of drug resistance of existing antibiotics is solved. # imgabs0 #

The invention belongs to the technical field of quantitative detection of microorganisms, and particularly relates to a method for quantitatively detecting the viable count of mycoplasma bovis. The method for quantitatively detecting the viable count of the mycoplasma bovis is finally obtained by exploring the linear relation between the protein concentration and the viable count of multiple batches of mycoplasma bovis liquid samples after optimization of experimental conditions such as bacterium liquid preservation conditions, ultrasonic crushing modes, crushing duration and sample treatment modes, and the method is good in stability, high in timeliness and high in accuracy. The detection result is accurate, and a convenient and effective method is provided for rapid detection of the viable count of the mycoplasma bovis liquid.

The invention discloses a fusion protein for diagnosing mycoplasma bovis infection as well as a preparation method and application of the fusion protein. According to the fusion protein disclosed by the invention, dominant B cell epitope peptides of two strong immunogenic lipoproteins of mycoplasma bovis are connected, mycoplasma bovis infection can be effectively distinguished, and the fusion protein is further used for preparing a detection product for diagnosing mycoplasma bovis infection. A detection product prepared from the fusion protein disclosed by the invention has excellent sensitivity and specificity, and is of great significance for improving the economic benefit of the cattle breeding industry.

The invention relates to an SNP (Single Nucleotide Polymorphism) marker primer pair related to swine tolerance mycoplasma pneumonia traits on swine chromosome 3 and application of the SNP marker primer pair. The site of the SNP marker is a molecular marker of a nucleotide site rs328087548 of a pig chromosome 3 in a reference sequence of an international pig genome version 11.1, and the SNP marker has T / C polymorphism. According to a primer pair for detecting the SNP marker, an upstream primer is SEQ ID NO: 2, and a downstream primer is SEQ ID NO: 3. The SNP marker provided by the invention can be applied to marker-assisted selection of swine mycoplasmal pneumonia resistant traits, and swine populations or strains resistant to swine mycoplasmal pneumonia traits are screened by identifying the genotype of the SNP marker. Establishment of the group or strain can improve the capability of tolerating swine mycoplasmal pneumonia and produce more social and economic benefits.

The invention discloses a pathogenic microorganism antigen passive agglutination semi-quantitative detection reagent and method based on sulfydryl modified gold nanoparticle covalent coupling, and belongs to the field of medical detection. According to the method, 50nm sulfydryl modified gold nanoparticles are used as a carrier, the 50nm sulfydryl modified gold nanoparticles and pathogenic microorganism antigens are subjected to sulfydryl-amino covalent coupling according to the mass ratio of 1: 50, accurate sealing through 0.5% BSA and centrifugal purification to prepare a 0.02 mg / mL liquid reagent, the antigen shedding rate is smaller than or equal to 5% after the liquid reagent is stored in a dark place at the temperature of 4 DEG C for 3 months, and the activity retention rate is larger than or equal to 97%. During detection, after serum is subjected to complement inactivation and dilution treatment and is incubated with the reagent at 37 DEG C for 1 hour, objective interpretation is realized by determining a semi-quantitative spectrum criterion that A650nm / A520nm is greater than or equal to 1.5, the sensitivity reaches 98.2%, and the specificity reaches 99.2%. The method can be popularized and applied to antibody detection of various pathogenic microorganisms such as mycoplasma pneumoniae and respiratory syncytial viruses, and the detection stability and objectivity are remarkably improved.

The present invention provides a primer-probe combination, a kit, and a method for detecting Mycoplasma alligatoris and Mycoplasma crocodyli using real-time fluorescence quantitative PCR. The nucleotide sequence of the primer-probe combination is shown in SEQ ID NOs: 1-3. The kit and detection method provided by the present invention can detect Mycoplasma alligatoris and Mycoplasma crocodyli in test samples. The kit and detection method have the characteristics of rapid detection, high sensitivity, and good specificity. These methods can have a positive impact on the prevention and control of mycoplasma diseases in crocodiles and alligators, as well as the development of related vaccines and drugs, and are conducive to the development of the crocodile and alligator breeding industries.

The invention discloses high-pathogenicity mycoplasma bovis and application thereof, and belongs to the technical field of microorganisms. The mycoplasma bovis is mycoplasma bovis, the number of the mycoplasma bovis is MbST201NMG1, and the mycoplasma bovis is registered in the China General Microbiological Culture Collection Center (CGMCC), and the registration number of the mycoplasma bovis is CGMCC No: 45661. The mycoplasma bovis provided by the invention is high in minimum inhibition concentration to antibiotics, low in adhesion rate to Mac-T cells but high in invasion rate, and can be used for establishing a more typical animal clinical lesion model of the mycoplasma bovis compared with other mycoplasma bovis, so that a certain support is provided for subsequent research and development of vaccines.

The present invention provides an electrochemical biosensor for the detection of Mycoplasma pneumoniae. The core includes a specific capture probe, and its nucleotide sequence is the complementary sequence of the 23S-5S rDNA internal transcribed spacer (ITS) of Mycoplasma pneumoniae. In the preparation process, a porous membrane is used as an efficient electron transfer channel, significantly simplifying the process and improving the reaction efficiency. With the capture probe targeting 23S-5S rDNA ITS, the sensor is endowed with excellent specificity and high sensitivity, enabling it to perform outstandingly in the detection of complex biological samples, accurately and efficiently identifying the target substance and effectively avoiding interference from other substances. The electrochemical biosensor of the present invention is easy to operate and has a fast response speed, with broad application prospects in the fields of clinical diagnosis and rapid disease screening. It can provide key technical support for the timely diagnosis of Mycoplasma pneumoniae infection, greatly meeting the urgent need for rapid and accurate detection in clinical and practical applications, and strongly promoting the development process of biological detection technology in the direction of Mycoplasma pneumoniae detection.

The invention provides a mycoplasma caninum, a culture method and application thereof. According to the invention, a new strain of mycoplasma canis is obtained through separation, the mycoplasma canis is named as QAU241017.16, and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 23, 2025, and the preservation number is CGMCC No. 46643. The isolates have eight amino acid site mutations on the sialidase gene, and animal experiments prove that the toxicity of the isolates is remarkably enhanced. The inactivated vaccine prepared from the mycoplasma canine has good immunogenicity and safety, and can effectively stimulate an organism to generate an antibody aiming at the mycoplasma canine. The inactivated vaccine prepared on the basis of the strain can induce the neutralizing antibody titer to be 1: 128. The invention can provide a new scheme for prevention and control of canine mycoplasma. Compared with a traditional culture method, the canine mycoplasma separation culture method provided by the invention is lower in cost, more efficient and capable of realizing rapid proliferation of mycoplasma and achieving higher viable bacterium titer. And a technical support is provided for isolated culture of the canine mycoplasma.

The invention discloses a recombinant chicken mycoplasma synoviae antigen protein as well as a coding gene, a preparation method and application thereof. A prokaryotic expression system is used for expressing and purifying rRS02775 recombinant protein, rRS01455 recombinant protein, rRS01745 recombinant protein, rRS01040 recombinant protein, rRS01750 recombinant protein and rRS02145 recombinant protein respectively, further, the multi-antibody serum prepared by immunizing BALB / c mice has a remarkable growth inhibition effect on a chicken mycoplasma synoviae WVU1853 strain, a Ningxia / 2017-1 strain and a Shandong / 2017-2 strain, the highest valence of a neutralizing antibody can reach 1: 256, and the multi-antibody serum has the potential of being used for developing chicken mycoplasma synoviae subunit vaccines.

The invention discloses high-pathogenicity mycoplasma bovis and application thereof, and belongs to the technical field of microorganisms. The mycoplasma bovis is mycoplasma bovis, the number of the mycoplasma bovis is MbST202TJ6, and the mycoplasma bovis is registered in the China General Microbiological Culture Collection Center (CGMCC), and the registration number of the mycoplasma bovis is CGMCC No: 45662. The mycoplasma bovis provided by the invention has high minimum inhibition concentration to antibiotics, high adhesion rate to Mac-T cells but low invasion rate, can be used for establishing a more typical animal clinical lesion model of the mycoplasma bovis compared with other mycoplasma bovis, and provides certain support for subsequent research and development of vaccines.

A composition and a kit for detecting mycoplasma are provided. The composition for detecting mycoplasma is an aqueous solution including a primer M-F, a primer M-R, and a probe M-P. A sequence of the M-F is shown in SEQ ID NO: 1. A sequence of the M-R is shown in SEQ ID NO: 2. A nucleotide sequence of the probe M-P is shown in SEQ ID NO: 3, and includes a fluorophore FAM linked at a 5′ terminus and a quencher BHQ1 linked at a 3′ terminus. The composition exhibits high sensitivity, strong specificity, and a wide detection range when used in the detection of mycoplasma.

The invention belongs to the technical field of antibody detection kits, and relates to an application of chicken mycoplasma synoviae recombinant protein FBA in preparation of a chicken mycoplasma synoviae antibody indirect ELISA detection kit, which is characterized in that the amino acid sequence of the chicken mycoplasma synoviae recombinant protein FBA is as shown in SEQ ID NO.1. The indirect ELISA detection kit for the chicken mycoplasma synoviae antibody is characterized by comprising an elisa plate which takes chicken mycoplasma synoviae recombinant protein FBA as a coating antigen, wherein the amino acid sequence of the chicken mycoplasma synoviae recombinant protein FBA is shown as SEQ ID NO.1. The method is helpful for deeply developing the research on chicken mycoplasma synoviae infection and immunity, and a rapid, sensitive and good-specificity method is provided for clinical diagnosis of chicken mycoplasma synoviae infection.

The present invention discloses a recombinant Mycoplasma synoviae antigen protein, its coding gene, preparation method and application. The present invention respectively expresses and purifies rRS02775, rRS01455, rRS01745, rRS01040, rRS01750, rRS02145 recombinant proteins by using a prokaryotic expression system. Furthermore, the polyclonal antiserum prepared by immunizing BALB / c mice has a significant growth inhibitory effect on Mycoplasma synoviae strains WVU1853, Ningxia / 2017-1, and Shandong / 2017-2. The neutralizing antibody titer can reach up to 1:256 at most, and it has the potential to be developed into a Mycoplasma synoviae subunit vaccine.

The invention provides a mycoplasma pneumoniae vaccine and application thereof. Specifically, the invention relates to a mycoplasma pneumoniae protein, a vaccine composition composed of the mycoplasma pneumoniae protein, a preparation method and medical application of the mycoplasma pneumoniae protein, and the vaccine composition has a good protection effect on mycoplasma pneumoniae infection, and can remarkably relieve weight loss, reduce lung pathogen load and reduce lung pathological score. The mycoplasma pneumoniae vaccine has extremely high application value in mycoplasma pneumoniae vaccine development.

The invention relates to a culture medium for culturing human mycoplasma pneumoniae and a culture method, and belongs to the technical field of microorganisms, the culture medium for culturing the human mycoplasma pneumoniae comprises a mycoplasma culture medium and a growth promoting additive, the growth promoting additive comprises horse serum or fetal calf serum, cholesterol, penicillin sodium and an HEPES buffer solution, according to the culture medium for culturing the human mycoplasma pneumoniae, various components are simple and easy to obtain, the preparation method of the culture medium is greatly simplified, and the efficiency is improved; according to the culture method of the human mycoplasma pneumoniae, the culture mode is changed from a static state to a dynamic state, so that the culture efficiency of the human mycoplasma pneumoniae is improved, and meanwhile, the thallus yield of the human mycoplasma pneumoniae is also improved; the culture method for preparing the human mycoplasma pneumoniae is short in period, low in cost, high in culture viable organism density and high in yield, and is suitable for large-scale culture of the human mycoplasma pneumoniae.

The invention provides a mycoplasma bovis specific antigen epitope peptide and application thereof in antibody detection, and the amino acid sequence of the antigen epitope peptide is SEQ ID NO: 1. Bioinformatics prediction and serological verification are carried out on mycoplasma bovis immunogenic protein, the antigen epitope peptide highly associated with antibody reaction specificity is obtained through screening, a high-specificity mycoplasma bovis antibody detection method can be established by using the epitope peptide, the detection specificity is 100%, the sensitivity is 98.8%, and the detection time is short. And an effective tool is provided for serological diagnosis of mycoplasma bovis infection.

Provided are a Mycoplasma hyopneumoniae subunit vaccine, a preparation method therefor, and use thereof, which belong to the field of animal vaccines. The Mycoplasma hyopneumoniae subunit vaccine uses a Mycoplasma hyopneumoniae fusion protein as an antigen, the amino acid sequence of which is set forth in SEQ ID NO: 1. The preparation method comprises the following steps: (1) preparing an aqueous phase containing the fusion protein; and (2) mixing an oil phase and the aqueous phase according to a volume ratio of 1:0.8-1.2, and emulsifying to obtain the vaccine. The Mycoplasma hyopneumoniae subunit vaccine can protect pigs effectively for a long time and provides an effective means for the prevention and control of Mycoplasma hyopneumoniae.

The invention discloses a mycoplasma gallisepticum RRF recombinant protein, a polyclonal antibody and a preparation method thereof, and belongs to the technical field of gene engineering. The amino acid sequence of the recombinant protein is as shown in SEQ ID NO: 1. The preparation method comprises the following steps: (1) transforming a recombinant protein vector into a competent cell, and constructing an engineering bacterium with a recombinant vector; (2) IPTG (isopropyl-beta-d-thiogalactoside) induces the engineering bacteria, expression of mycoplasma gallisepticum RRF recombinant protein is performed, purification is performed, and the mycoplasma gallisepticum The polyclonal antibody is prepared by performing animal immunization by using mycoplasma gallisepticum RRF recombinant protein; the preparation method comprises the following steps: (1) immunizing animals by using mycoplasma gallisepticum RRF recombinant protein as an antigen; and (2) obtaining animal serum and purifying the animal serum. The anti-mycoplasma gallisepticum RRF polyclonal antibody disclosed by the invention can specifically recognize endogenous RRF protein of mycoplasma gallisepticum, is used for ELISA (Enzyme-Linked Immunosorbent Assay) and WesternBlot experiments, and provides a material basis for researching RRF functions.

The invention provides a mycoplasma pneumoniae polypeptide epitope with immunogenicity. The mycoplasma pneumoniae polypeptide epitope is a polypeptide epitope which is from mycoplasma pneumoniae type I and type II and adheres to key protein P1, P30, P40 / 90, P116 and / or CARDS toxin. The invention also provides a recombinant protein which contains more than one mycoplasma pneumoniae polypeptide epitope with immunogenicity. The invention further provides a vaccine for preventing mycoplasma pneumoniae infection, the vaccine provides protection against infection of at least one of mycoplasma pneumoniae type I and / or type II, and the vaccine is characterized by comprising the recombinant protein. According to the present invention, it is possible to provide a safe and effective vaccine for preventing mycoplasma pneumoniae infection.

The invention provides a chicken mycoplasma synoviae subunit vaccine, a preparation method, detection and application thereof. The chicken mycoplasma synoviae VY930 protein expressed on the basis of an escherichia coli prokaryotic expression system has good immunogenicity, and a subunit vaccine containing the protein is prepared from the chicken mycoplasma synoviae VY930 protein so as to effectively prevent and control chicken mycoplasma synoviae infection. Animal challenge protection tests prove that the subunit vaccine has immune protection potential equivalent to or slightly superior to that of an inactivated vaccine, and clinical symptoms caused by the mycoplasma synoviae can be remarkably relieved. The subunit vaccine disclosed by the invention is simple and convenient in preparation process and low in cost, can adapt to a large-scale production mode, and has the potential of preventing and controlling clinical infection of the mycoplasma synoviae and promoting a population purification process. The invention further provides a monoclonal antibody aiming at the protein, the monoclonal antibody can be used as an index for judging whether immunization is carried out or not, meanwhile, the immune protection evaluation criterion after chicken mycoplasma synoviae foot pad challenge is refined, and a meticulous measurement standard is provided for follow-up vaccine research and development.

The present application relates to the technical field of veterinary biological products, in particular to a mycoplasma hyopneumoniae fusion protein and a preparation method and application thereof.The mycoplasma hyopneumoniae fusion protein has an amino acid sequence comprising a mycoplasma hyopneumoniae P46 protein, a mycoplasma hyopneumoniae P65 protein and a rigid linker peptide;the amino acid sequence of the mycoplasma hyopneumoniae P46 protein is shown as SEQ ID NO.7;the amino acid sequence of the mycoplasma hyopneumoniae P65 protein is shown as SEQ ID NO.8;and the amino acid sequence of the rigid linker peptide is EAAAK.When the mycoplasma hyopneumoniae fusion protein is used for detection, the sensitivity is good, the repeatability is good, no cross reaction with other antibodies is generated, the specificity is strong, and the accuracy is obviously higher than that of the IDEXX method.The mycoplasma hyopneumoniae fusion protein can be used for clinical sample detection and pig herd immune level monitoring.

The invention belongs to the technical field of biology, and particularly relates to application of a chicken early growth response factor-1 (EGR1) in resisting Mycoplasma gallisepticum (MG) infection, in particular to application of the EGR1 in resisting Mycoplasma gallisepticum (MG) infection. The invention finds that after MG infects chicken macrophages (HD11), the EGR1 expression level is obviously increased. After EGR1 is further overexpressed or interfered in cells, MG challenge discovers that overexpressed EGR1 can remarkably promote replication and adhesion of MG in the cells, and interference EGR1 can remarkably inhibit replication and adhesion of MG in the cells, inhibit release of proinflammatory factors and promote release of anti-inflammatory factors. The EGR1 is a susceptible gene of MG infection, and the MG resistance of cells can be remarkably improved by interfering the expression of the EGR1. Therefore, the expression of silent EGR1 gene is helpful for the body to resist MG infection, and a new molecular marker is provided for molecular marker-assisted selective breeding.

This invention relates to a novel fusion protein, immunogenic composition, recombinant vaccine, molecular architecture design, and applications for the prevention and treatment of Mycoplasma pneumoniae infection. The invention provides a novel fusion molecular architecture comprising fusion proteins encoded by the PstS and P37 genes, which can be used in the development of nucleic acid vaccines. The invention reveals that the novel fusion protein exhibits excellent immunogenicity, providing effective immune protection, significantly inhibiting Mycoplasma pneumoniae colonization, and, compared to nucleic acid vaccines encoding the P1-P30 fusion protein, which are known in the art to have excellent efficacy, demonstrates a more significant immune effect and protective effect against Mycoplasma pneumoniae infection, showing broad application prospects.

The invention belongs to the field of biology, and discloses a plasmid which contains a haemophilus parasuis Omp Am outer membrane protein gene and a mycoplasma hyopneumoniae membrane protein gene. The mycoplasma hyopneumoniae membrane protein gene is one or a combination of more of a mycoplasma hyopneumoniae membrane protein P46 gene, a mycoplasma hyopneumoniae membrane protein P65 gene and a mycoplasma hyopneumoniae membrane protein P159 gene. The plasmid contains an Omp Am outer membrane protein gene and a mycoplasma hyopneumoniae membrane protein gene, recombinant haemophilus parasuis is prepared from a target gene amplified from the vector through a primer in a natural transformation mode, one or more of Mhp antigen proteins such as P46 protein, P65 protein and P159 protein can be effectively expressed, and the effect of double immunization is achieved. Meanwhile, the invention also provides recombinant haemophilus parasuis and application thereof.